JPRN-UMIN000009765已完成2 期
Bortezomib, cyclophosphamide plusd dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma - VCD treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. severe renal damage: Ccr <30mL/min even after correction of dehydration and hypercalcemia 2.severe cardiac dysfunction: angina pectoris or acute myocardial infarction within 6 months of enrollment, congestive heart failure requiring medical treatment or arrhythmia requiring medical treatment. 3.severe respiratory dysfunction: SpO2 <= 93%, interstitial pneumonitis, chronic obstructive pulmonary disease, active pneumonia 4.infection 4-1HIV positive 4-2HBs antigen positive 4-3HBs antibody positive and/or HBc antibody positive and HBV-DNA positive 4-4HCV antibody positive 5.peripheral neuropathy > grade 2 6.Uncontrolled diabetes mellitus 7.others 7-1active double cancer 7-2pregnancy or breastfeeding 7-3doctor judged adequate to enroll the study
研究者
相似试验
尚未招募
3 期
A comparison of Bortezomib, Pomalidomide with low-dose Dexamethasone and Bortezomib, Lenalidomide with low-dose dexamethasone for newly-diagnosed multiple myeloma patients- A randomized phase III study.CTRI/2019/07/020397Dr Lalit Kumar
进行中（未招募）
不适用
Bortezomib, Rituximab, and Dexamethasone (BORID), followed by Rituximab maintenance, for patients with relapsed/refractory mantle cell lymphoma - BORID in relapsed mantle cell lymphomarelapsed mantle cell lymphomaEUCTR2004-002150-64-ATMedical University Vienna, Dept. of Medicine I, Clinical Division of Oncology16
终止
不适用
Bortezomib with lenalidomide and dexamethasone combination as induction therapy in transplantation candidate patients with newly diagnosed multiple myelomaKCT0004005The Catholic University of Korea, Seoul St. Mary's Hospital74
已完成
2 期
Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma RelapseMultiple MyelomaACTRN12606000180516Peter MacCallum Cancer Centre100
进行中（未招募）
不适用
Bendamustine, Bortezomib and Dexamethasone (BVD) in the treatment of relapsed or refractory Multiple Myeloma - BVD-CLEM 01-10Relapsed or refractory multiple myelomaMedDRA version: 9.1Level: LLTClassification code 10051381EUCTR2010-020072-33-ITAZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI